TAVI.today
Home
Latest Developments
Treatment & Guidelines
Clinical Evidence
Resources
Sign-up to Newsletter
Language: English
Language: English
Deutsch
Italian
Spanish

TAVI.today

edwards-logo-2-1-1.svg
Clinical evidence

Intermediate Risk Trial

PARTNER IIA Trial - TAVI shows similar outcomes compared to sAVR1

  • A large prospective, multicentre trial enrolling intermediate-risk severe aortic stenosis (sAS) patients randomised to either TAVI or surgery (sAVR)
  • The rate of the composite of all-cause mortality or disabling stroke at 2 years (primary endpoint) was non-inferior with TAVI and sAVR
  • In the transfemoral-access cohort (76% of patients), TAVI was superior to sAVR with regards to the primary endpoint
  • Compared with sAVR, TAVI resulted in shorter recovery times and a faster return to mobility and home
Clinician-with-patient

The PARTNER IIA Trial study design1

Partner IIA study design graph

Inclusions1

  • Severe aortic valve stenosis

    • Aortic valve area <0.8 cm2 or AVA index <0.5 cm2/m2
    • Mean gradient >40 mmHg or jet velocity >4.0 m/s
  • Symptoms of AS (NYHA class ≥II)
  • Intermediate surgical risk (STS score ≥4% and decision by a Heart Team)

Exclusions1

 

  • Heart Team assessment of inoperability
  • Evidence of an acute myocardial infarction ≤1 month (30 days) before the intended treatment
  • Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is noncalcified
  • Other anatomical or clinical features that increased the risk of complications associated with either TAVI or sAVR or factors that could confound the results

The baseline characteristics of the patients in the TAVI and sAVR groups were generally well balanced in the two groups with the exception of higher peripheral vascular disease (27.9% vs 32.9%, p=0.02) and atrial fibrillation (31.0 vs 35.2%, p=0.05) in the sAVR group.1*
TAVI (n=1,011)
sAVR (n=1,021)
Age
81.5 ± 6.7
81.7 ± 6.7
Male
54.2%
54.8%
BMI – kg / m2†
28.6 ± 6.2
28.3 ± 6.2
STS score‡
5.8 ± 2.1
5.8 ± 1.9
NYHA (III or IV)
77.3%
76.1%
Coronary artery disease
69.2%
66.5%
Peripheral vascular disease
27.9%
32.9%
Diabetes
37.7%
34.2%
COPD
31.8%
30.0%
Creatinine > 2 mg/dL§
5.0%
5.2%
Frailty condition
5-Meter walk-test time > 7 sec
44.4%
46.4%
Serum albumin < 3.5 g/dl
15.2%
14.7%
Atrial fibrillation
31.0%
35.2%
Permanent pacemaker
11.7%
12.0%
Liver disease
1.9%
2.5%
Plus–minus values are means ±SD. The body-mass index is the weight in kilograms divided by the square of the height in metres. Scoring on the risk model of the Society of Thoracic Surgeons (STS) uses an algorithm that is based on the presence of coexisting illnesses in order to predict 30-day operative mortality. The STS score equals the predicted mortality expressed as a percentage. Less than 5% of patients in the population on which the STS algorithm is based had a predicted operative mortality (risk score) of more than 10%. To convert values for creatinine to micromoles per litre, multiply by 88.4.

Reported clinical and patient outcomes

Quality of life

Patients receiving transfemoral TAVI enjoyed an improved health status through 2 years of follow-up after the procedure from baseline, as measured using the KCCQ-OS (Kansas City Cardiomyopathy Questionnaire – Overall Summary)2

Quality of life - intermediate risk patients

Patients receiving transfemoral TAVI also had more rapid health status improvements compared to sAVR.2  

 

Find out more about the QoL analysis and see the full outcome data

Real-world setting

TAVI has demonstrated similar efficacy in intermediate-risk patients to clinical trials3,4

 

  • ACC/STS TVT Registry: Propensity score matched 30-day outcomes showed no differences in all-cause mortality, all strokes and rates of new pacemakers between the ACC/STS TVT Registry, the PARTNER II S3i Trial and the S3i continued access registry3
  • SOLACE AU Registry: At 1 year, the rates of death, major vascular complications, acute kidney injury, life-threatening or disabling bleeding, and reintervention were 8.6%, 3.0%, 1.25%, 1.1% and 1.5% respectively4

Clinical implications

What could a TAVI referral mean for your patients who match the PARTNER IIA Trial characteristics?

  • Lowering your patients’ risk of death or disabling stroke through 2 years vs sAVR1
  • A speedy recovery to help patients to get back to the life they love1
  • Meaningful, early and late health status benefits which could give your patients the opportunity for a fuller life2
PARTNER IIA Trial clinical paper

Related resources

Print
Edwards TAVI study compendium
In-depth summary of the key Edwards Lifescience TAVI studies.
Download
Print
PARTNER 3 Trial outcomes
PARTNER 3 Trial outcomes summary
Infographic comparing SAPIEN 3 TAVI with sAVR in patients with severe aortic stenosis at low surgical risk.
Download
PDF
Tavi durability overview
TAVI durability overview
A summary of the current durability data (up to 8 years) for TAVI valves.
Download

Stay informed with our newsletter

By providing your personal information, you agree to allow Edwards Lifesciences and its agents to use this information to communicate with you in the future, including information about services, events, and programs. Edwards Lifesciences and its agents will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Edwards Lifesciences and its agents, Edwards Lifesciences will use your information in accordance with the Edwards privacy policy.
Our monthly updates provide you the latest developments in TAVI and aortic stenosis.     Read more

References

  • 1Leon MB, et al. N Engl J Med 2016;374:1609-1620 and supplementary material.
  • 2 Baron SJ, et al. JAMA Cardiol 2017;2(8) 837-845.
  • 3 Tuzcu M. Presentation at EuroPCR, May 22‒25, 2018; Paris, France.
  • 4 Walters D, et al. JACC 2016;68(18):B275‒B276.

Share this page on:

Facebook Twitter Linkedin Envelope
Latest Developments

Treatment & Guidelines

Clinical Evidence
Resources

Contact Edwards

Sitemap
Privacy Policy

Legal Terms

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable). Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity. 

Edwards, Edwards Lifesciences, the stylized E logo, PARTNER, PARTNER II, PARTNER 3, SAPIEN, and SAPIEN 3 are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners. 

© 2023 Edwards Lifesciences Corporation. All rights reserved. PP–EU-0771  v1.0

Stäng filmen

Help us create better content with 3 short questions.

Content relating to Tavi.today is intended for healthcare professionals. Click OK to confirm you are a healthcare professional and proceed.
OK
Skip to content